Fundraising Fox

Aminex Therapeutics

Kenmore, US · Washington corporation

Biotech

Founders & leadership

MB
Mark BurnsExecutive
SH
Stacy HockNamed on SEC filing
RU
Roger UlrichNamed on SEC filing
TG
Thomas GrahamNamed on SEC filing
RR
Rhonda RhyneNamed on SEC filing

Board

JR
John RoslingBoard director
DM
Donald MowatBoard director
DA
Deyaa AdibBoard director
JS
James SkaggsBoard director
JM
Jeffrey MillerBoard director
DM
David MeeksBoard director
DD
Don DyerBoard director

Reported raises · per SEC filings

Form D private placements

$34.5M disclosed across 6 rounds · 2014–2022

▶$15.1MraisedDec 2025 · 162 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Deyaa AdibDirector
  • James SkaggsDirector
  • Mark BurnsExecutive Officer, Director
  • Jeffrey MillerDirector
  • David MeeksDirector
  • Don DyerDirector
Offering amount
$30M
Amount sold
$15.1M
First sale
Oct 2022
Incorporated
Corporation, Washington
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.3MraisedAug 2021 · 97 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Larry RichardsExecutive Officer
  • James SkaggsExecutive Officer, Director
  • Mark BurnsExecutive Officer, Director
  • Roger UlrichDirector
  • Jeff MillerDirector
  • Rhonda RhyneDirector
  • Stacy HockDirector
Offering amount
$9.1M
Amount sold
$6.3M
Minimum investment
$2
First sale
Aug 2021
Incorporated
Corporation, Washington
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.9MraisedAug 2020 · 96 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark BurnsExecutive Officer, Director
  • James SkaggsExecutive Officer, Director
  • Stacy HockDirector
  • Roger UlrichDirector
  • Rhonda RhyneDirector
  • Jeff MillerDirector
Offering amount
$3M
Amount sold
$2.9M
First sale
Jul 2020
Incorporated
Corporation, Washington
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8.3MraisedJun 2018 · 96 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Stacy HockDirector
  • Mark BurnsExecutive Officer, Director
  • Roger UlrichDirector
  • Thomas GrahamExecutive Officer, Director
  • Jeff MillerDirector
  • Rhonda RhyneDirector
  • James SkaggsExecutive Officer, Director
Offering amount
$14.2M
Amount sold
$8.3M
First sale
May 2018
Incorporated
Corporation, Washington
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$410KraisedNov 2014 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John RoslingDirector
  • Mark BurnsExecutive Officer, Director
  • Jeff MillerDirector
  • James SkaggsDirector
  • Thomas GrahamExecutive Officer, Director
Offering amount
$2.4M
Amount sold
$410K
First sale
Oct 2014
Incorporated
Corporation, Washington
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.6MraisedJul 2014 · 22 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark BurnsExecutive Officer, Director
  • Thomas GrahamExecutive Officer, Director
  • John RoslingDirector
  • Donald MowatDirector
  • James SkaggsExecutive Officer, Director
Offering amount
$1.8M
Amount sold
$1.6M
First sale
Jun 2014
Incorporated
Corporation, Washington
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Aminex Therapeutics Announces Multiple Sites Activated for Phase 1b/2 Clinical Trial of Novel Investigational Cancer Treatment AMXT 1501 and DFMO in Patients with Breast Cancer or Melanomaprnewswire.com · Feb 2026Beat Childhood Cancer Research Consortium at Penn State College of Medicine and Aminex Therapeutics announce national clinical trial for pediatric patients with high-risk cancers - Penn State Health Newspennstatehealthnews.org · Oct 2025BioCentury - Aminex raises $10M, starts Phase I cancer trialbiocentury.com · Jun 2018Startup Aminex Therapeutics raises $10M, begins clinical trials of immunotherapy treatment – GeekWiregeekwire.com · Jun 2018Aminex Therapeutics, Inc. Closes $4M Series A Financingprnewswire.com · Nov 2015

Frequently asked questions

How much funding has Aminex Therapeutics raised?
Aminex Therapeutics has disclosed $34.5M raised across 6 rounds.
Where is Aminex Therapeutics headquartered?
Aminex Therapeutics is headquartered in Kenmore, US.